April 2, 2018 9:03am
Volatility, algorithms, ETFs and cash positions along with who needs to “tap” the capital markets for continued survival?
How are enrollments going as to population and are they sustainable re drop-outs? Has the data from on-going trials been interpreted as to render measureable and definitive outcomes? Is the company partnered to ward-off the issues of dilution and share depreciation!
And finally, trend analysis – do momentum’s magnitude, technicals and fundamentals indicate expected pricing performance in 2018?
Why spend time finding sector news and analytics … it’s all right here! Review daily indicators, factors and trend lines, advance/decline lines of 40 covered companies, pre-open indicator results and volatility and of the % count of decliners versus gainers.
Learn who is stumbling and what the mumbling means …
For 8 years, RMi is the only source of actionable intelligence for the stem, cell and gene therapy and regenerative medicine’s universe.
You’ve enjoyed complimentary access to unbiased analysis, in-depth analytics, and informational synthesis along with RMi’s exclusive listing of “our” universe’s stocks and their potential for gains and losses; but exclusivity is now here. Access to RegMed Investors’ targeted content is by subscription.
For continued access to what one industry CEO calls the “Bible” for smart investing in the RegMed, gene and cell therapy sector, click on the button below:
http://www.regmedinvestors.com/create-account
